Merus (MRUS) delivered a "flawless victory" in its interim data of the mid-stage study of petosemtamab plus pembrolizumab in head and neck squamous cell carcinoma, Truist Securities said in a Thursday note.
The study's results showing a 79% overall survival rate at 12-month was "unquestionably stronger" than competing treatment of ficerafusp alfa with pembrolizumab, Truist analysts said.
"These data reinforce our view that Peto is best-in-class," they said. "We are encouraged by MRUS indicating that data from one or both Phase 3 programs could be reported in 2026."
Truist reiterated its buy rating with a price target of $88.
Price: 54.26, Change: +12.66, Percent Change: +30.43
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。